LAS INFECCIONES DE TRANSMISIÓN SEXUAL. - Euskadi.net

16. Barlam TF. Expedited treatment for partners
of patients with gonorrhea and/or
chlamydial infection: impact on rates of
persistence or recurrence. Postgrad Med
2005 May; 117(5):6.
17. Berkhof J, de Bruijne MC, Zielinski GD,
Meijer CJ. Natural history and screening
model for high-risk human papillomavirus
infection, neoplasia and cervical cancer
in the Netherlands. Int J Cancer 2005
Jun 10; 115(2):268-75.
18. Bhave G, Lindan CP, Hudes ES et al. Impact
of an intervention on HIV, sexually
transmitted diseases, and condom use
among sex workers in Bombay, India.
AIDS (London, England) 1995; 9 Suppl
1:S21-30.
19. Bleeker M, Hogewoning C, Voorhorst F,
Van den Brule A, Snijders P, Starink T, et
al. Condom use promotes regression of
human papillomavirus-associated penile
lesions in male sexual partners of women
with cervical intraepithelial neoplasia.
Int J Cancer 2003; 107; 804-10.
20. Bosch FX, Lorincz A, Muñoz N, Meijer
CJLM, Shah KV. The causal relation between
human papillomavirus and cervical
cancer. J Clin Pathol 2002; 55:244-265.
21. Bosch FX. The worldwide prevalence of
HPV, paper presented to the HPV
1999summit of the National HPV and Cervical
Cancer Resource Centre, American
Social Health Asssociation, Chamonix,
France 8-10 February [Internet]. 1999.
22. Bosch FX, Manos MM, Munoz N, Sherman
M, Jansen AM, Peto J, Schiffman
MH, Moreno V, Kurman R, Shah KV. Prevalence
of human papillomavirus in cervical
cancer: a worldwide perspective. International
biological study on cervical
cancer (IBSCC) Study Group. J Nat Cancer
Instit 1995, 87 (11), 796-802.
23. Bray F, Loos AH, McCarron P, Weiderpass
E, Arbyn M, Moller H, Hakama M, Parkin
DM. Trends in cervical squamous cell carcinoma
incidence in 13 European countries:
changing risk and the effects of
screening. Cancer Epidemiol Biomarkers
Prev 2005 Mar; 14(3):677-86.
24. British Screening Guidelines Steering
Commmitee. Sexually transmitted infections
screening and testing guidelines.
Draf 12/01/2006. Comunicación personal.
25. Brown DR, Fife KH, Wheeler CM, Koutsky
LA, Lupinacci LM, Railkar R, Suhr G, Barr E,
Dicello A, Li W, Smith JF, Tadesse A, Jansen
KU. Early assessment of the efficacy
of a human papillomavirus type 16 L1 virus-like
particle vaccine. Vaccine 2004 Jul
29; 22(21-22):2936-42.
26. Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst
FJ, Snijders PJ, Meijer CJ. Prevalence
of types 16 and 33 is increased in
high-risk human papillomavirus positive
women with cervical intraepithelial neoplasia
grade 2 or worse. Int J Cancer 2005
May 17; 117 (2):177-181.
27. Bulkmans NW, Rozendaal L, Voorhorst FJ,
Snijders PJ, Meijer CJ. Long-term protective
effect of high-risk human papillomavirus
testing in population-based cervical
screening. Br J Cancer 2005 May 9; 92
(9):1800-2.
28. Bunnell RE, Dahlberg L, Rolfs R, Ransom
R, Gershman K, Farshy C, Newhall WJ,
Schmid S, Stone K, St Louis M. High prevalence
and incidence of sexually transmitted
diseases in urban adolescent females
despite moderate risk behaviors. J
Infect Dis 1999 Nov; 180(5):1624-31.
29. Cabello L, Arce A, Burgoa M, Moreno C.
¿Resurge el viejo problema de la sífilis
Estudio en un área de Madrid. Gac Sanit
2004; 18 (Supl 3): 92.
30. Carey M, Maisto S, Kalichman S, Forsyth
A, Wright E, Johnson B. Enhancing motivation
to reduce the risk of HIV infection
for economically disadvantaged urban
women. Journal of consulting and clinical
psychology 1997; 65(4):531-41.
158